Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...

Called Spravato, a brand name for esketamine, and developed by Johnson & Johnson, the drug is a nasal spray designed to treat severe forms of depression that don't respond to other medications.

The nasal spray had to go through many rounds of clinical testing, with some shown to improve depression, while others showed no improvement over a placebo. In 2019, the FDA approved Spravato for ...

We can help. Stella Mental Health in New York specializes in Spravato (esketamine) nasal spray, ketamine infusion therapy, stellate ganglion blocks (SGB) and integration therapy. Schedule an ...

The remaining 20% is their coinsurance. S-ketamine, or esketamine (Spravato), is an FDA-approved nasal spray that doctors and healthcare professionals may prescribe for major depressive disorder ...